Detect neurodegenerative disease earlier.
Vivid Genomics enables pharma companies to select and stratify the right patients for their clinical trials, increasing the probability of trial success and drug approval.
Our first two tests will address features of Alzheimer’s disease:
AmyloidGB™ Predicts the presence of amyloid plaques, a hallmark of Alzheimer’s disease for precision patient enrollment, enriching the subset of patients who will be positive in Amyloid PET. ProgressionGB™ Provides information on predicted Alzheimer’s disease progression rate for precision balancing of the trial arms. It can be used for retrospective analysis to determine if a trial would have been successful by balancing for progression rate or removal of non-progressors.
Alzheimer's Disease
Early detection through biomarker analysis helps physicians identify cognitive decline before symptoms progress, enabling timely intervention.
Parkinson's Disease
Genomic Biopsy identifies pathological markers that reveal Parkinson's progression, allowing physicians to start treatment earlier and slow neurological decline.
ALS (Amyotrophic Lateral Sclerosis)
Early ALS detection through cerebrospinal fluid biomarkers enables faster diagnosis and enrollment in clinical trials, advancing both individual care and research.
Ready to learn more about Genomic Biopsy?
Contact Vivid Genomics to discuss early detection testing, research partnerships, or clinical implementation for your practice.